Selected research
Industry Research
RNA Polymerase Inhibitor Industry Research Report 2026
Market perspective
The global RNA Polymerase Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for RNA Polymerase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for RNA Polymerase Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for RNA Polymerase Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of RNA Polymerase Inhibitor include Johnson & Johnson, Merck, Pfizer, GlaxoSmithKline, AbbVie, AstraZeneca, Sierra Oncology, Repare Therapeutics and Karyopharm Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global RNA Polymerase Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
RNA Polymerase Inhibitor Market by Company
Johnson & Johnson
Merck
Pfizer
GlaxoSmithKline
AbbVie
AstraZeneca
Sierra Oncology
Repare Therapeutics
Karyopharm Therapeutics
Genentech
Clovis Oncology
Bristol Myers Squibb
Artios Pharma
RNA Polymerase Inhibitor Segment by Type
Rucaparib
Niraparib
Talazoparib
Veliparib
Others
RNA Polymerase Inhibitor Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
RNA Polymerase Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Polymerase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA Polymerase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Polymerase Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of RNA Polymerase Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of RNA Polymerase Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of RNA Polymerase Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rucaparib
- Niraparib
- Talazoparib
- Veliparib
- Others
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Johnson & Johnson
- Merck
- Pfizer
- GlaxoSmithKline
- AbbVie
- AstraZeneca
- Sierra Oncology
- Repare Therapeutics
- Karyopharm Therapeutics
- Genentech
- Clovis Oncology
- Bristol Myers Squibb
- Artios Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global RNA Polymerase Inhibitor Market Size (2021-2032)
- 2.2.2 Global RNA Polymerase Inhibitor Sales (2021-2032)
- 2.2.3 Global RNA Polymerase Inhibitor Market Average Price (2021-2032)
- 2.3 RNA Polymerase Inhibitor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rucaparib
- 2.3.3 Niraparib
- 2.3.4 Talazoparib
- 2.3.5 Veliparib
- 2.3.6 Others
- 2.4 RNA Polymerase Inhibitor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global RNA Polymerase Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global RNA Polymerase Inhibitor Sales (K Tons) of Manufacturers (2021-2026)
- 3.3 Global RNA Polymerase Inhibitor Revenue of Manufacturers (2021-2026)
- 3.4 Global RNA Polymerase Inhibitor Average Price by Manufacturers (2021-2026)
- 3.5 Global RNA Polymerase Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of RNA Polymerase Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of RNA Polymerase Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of RNA Polymerase Inhibitor, Established Date
- 3.9 Global RNA Polymerase Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson RNA Polymerase Inhibitor Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck RNA Polymerase Inhibitor Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer RNA Polymerase Inhibitor Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 GlaxoSmithKline
- 4.4.1 GlaxoSmithKline Company Information
- 4.4.2 GlaxoSmithKline Business Overview
- 4.4.3 GlaxoSmithKline RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline RNA Polymerase Inhibitor Product Portfolio
- 4.4.5 GlaxoSmithKline Recent Developments
- 4.5 AbbVie
- 4.5.1 AbbVie Company Information
- 4.5.2 AbbVie Business Overview
- 4.5.3 AbbVie RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie RNA Polymerase Inhibitor Product Portfolio
- 4.5.5 AbbVie Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca RNA Polymerase Inhibitor Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Sierra Oncology
- 4.7.1 Sierra Oncology Company Information
- 4.7.2 Sierra Oncology Business Overview
- 4.7.3 Sierra Oncology RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sierra Oncology RNA Polymerase Inhibitor Product Portfolio
- 4.7.5 Sierra Oncology Recent Developments
- 4.8 Repare Therapeutics
- 4.8.1 Repare Therapeutics Company Information
- 4.8.2 Repare Therapeutics Business Overview
- 4.8.3 Repare Therapeutics RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Repare Therapeutics RNA Polymerase Inhibitor Product Portfolio
- 4.8.5 Repare Therapeutics Recent Developments
- 4.9 Karyopharm Therapeutics
- 4.9.1 Karyopharm Therapeutics Company Information
- 4.9.2 Karyopharm Therapeutics Business Overview
- 4.9.3 Karyopharm Therapeutics RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Karyopharm Therapeutics RNA Polymerase Inhibitor Product Portfolio
- 4.9.5 Karyopharm Therapeutics Recent Developments
- 4.10 Genentech
- 4.10.1 Genentech Company Information
- 4.10.2 Genentech Business Overview
- 4.10.3 Genentech RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Genentech RNA Polymerase Inhibitor Product Portfolio
- 4.10.5 Genentech Recent Developments
- 4.11 Clovis Oncology
- 4.11.1 Clovis Oncology Company Information
- 4.11.2 Clovis Oncology Business Overview
- 4.11.3 Clovis Oncology RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Clovis Oncology RNA Polymerase Inhibitor Product Portfolio
- 4.11.5 Clovis Oncology Recent Developments
- 4.12 Bristol Myers Squibb
- 4.12.1 Bristol Myers Squibb Company Information
- 4.12.2 Bristol Myers Squibb Business Overview
- 4.12.3 Bristol Myers Squibb RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol Myers Squibb RNA Polymerase Inhibitor Product Portfolio
- 4.12.5 Bristol Myers Squibb Recent Developments
- 4.13 Artios Pharma
- 4.13.1 Artios Pharma Company Information
- 4.13.2 Artios Pharma Business Overview
- 4.13.3 Artios Pharma RNA Polymerase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Artios Pharma RNA Polymerase Inhibitor Product Portfolio
- 4.13.5 Artios Pharma Recent Developments
5 Global RNA Polymerase Inhibitor Market Scenario by Region
- 5.1 Global RNA Polymerase Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global RNA Polymerase Inhibitor Sales by Region: 2021-2032
- 5.2.1 Global RNA Polymerase Inhibitor Sales by Region: 2021-2026
- 5.2.2 Global RNA Polymerase Inhibitor Sales by Region: 2027-2032
- 5.3 Global RNA Polymerase Inhibitor Revenue by Region: 2021-2032
- 5.3.1 Global RNA Polymerase Inhibitor Revenue by Region: 2021-2026
- 5.3.2 Global RNA Polymerase Inhibitor Revenue by Region: 2027-2032
- 5.4 North America RNA Polymerase Inhibitor Market Facts & Figures by Country
- 5.4.1 North America RNA Polymerase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America RNA Polymerase Inhibitor Sales by Country (2021-2032)
- 5.4.3 North America RNA Polymerase Inhibitor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe RNA Polymerase Inhibitor Market Facts & Figures by Country
- 5.5.1 Europe RNA Polymerase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe RNA Polymerase Inhibitor Sales by Country (2021-2032)
- 5.5.3 Europe RNA Polymerase Inhibitor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific RNA Polymerase Inhibitor Market Facts & Figures by Country
- 5.6.1 Asia Pacific RNA Polymerase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific RNA Polymerase Inhibitor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific RNA Polymerase Inhibitor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America RNA Polymerase Inhibitor Market Facts & Figures by Country
- 5.7.1 South America RNA Polymerase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America RNA Polymerase Inhibitor Sales by Country (2021-2032)
- 5.7.3 South America RNA Polymerase Inhibitor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa RNA Polymerase Inhibitor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa RNA Polymerase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa RNA Polymerase Inhibitor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa RNA Polymerase Inhibitor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global RNA Polymerase Inhibitor Sales by Type (2021-2032)
- 6.1.1 Global RNA Polymerase Inhibitor Sales by Type (2021-2032) & (K Tons)
- 6.1.2 Global RNA Polymerase Inhibitor Sales Market Share by Type (2021-2032)
- 6.2 Global RNA Polymerase Inhibitor Revenue by Type (2021-2032)
- 6.2.1 Global RNA Polymerase Inhibitor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global RNA Polymerase Inhibitor Revenue Market Share by Type (2021-2032)
- 6.3 Global RNA Polymerase Inhibitor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global RNA Polymerase Inhibitor Sales by Application (2021-2032)
- 7.1.1 Global RNA Polymerase Inhibitor Sales by Application (2021-2032) & (K Tons)
- 7.1.2 Global RNA Polymerase Inhibitor Sales Market Share by Application (2021-2032)
- 7.2 Global RNA Polymerase Inhibitor Revenue by Application (2021-2032)
- 7.2.1 Global RNA Polymerase Inhibitor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global RNA Polymerase Inhibitor Revenue Market Share by Application (2021-2032)
- 7.3 Global RNA Polymerase Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 RNA Polymerase Inhibitor Value Chain Analysis
- 8.1.1 RNA Polymerase Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 RNA Polymerase Inhibitor Production Mode & Process
- 8.2 RNA Polymerase Inhibitor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 RNA Polymerase Inhibitor Distributors
- 8.2.3 RNA Polymerase Inhibitor Customers
9 Global RNA Polymerase Inhibitor Analyzing Market Dynamics
- 9.1 RNA Polymerase Inhibitor Industry Trends
- 9.2 RNA Polymerase Inhibitor Industry Drivers
- 9.3 RNA Polymerase Inhibitor Industry Opportunities and Challenges
- 9.4 RNA Polymerase Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst